Recombinant Human SMARCA4, GST-tagged

• Cat.No.: SMARCA4-1916H
• Product Overview: Recombinant Human SMARCA4(a.a. 1480-1603), fused with N-terminal GST-tag, was expressed in an E. coli expression system.

Specification

• Description: The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene.
• Source: E. coli
• Species: Human
• Tag: GST
• Form: 40 mM Tris-HCl, pH 8.0,110 mM NaCl, 2.2 mM KCl, and 20% glycerol.
• Molecular Mass: 41.3 kDa
• Protein length: 1480-1603
• AA Sequence: MSPILGYWKIKGLVQPTRLLLEYLE EKYEEHLYERDEGDKWRNKKFELGL EFPNLPYYIDGDVKLTQSMAIIRY IADKHNMLGGCPKERAEISMLEGAV LDIRYGVSRIAYSKDFETLKVDFLS KLPEMLKMFEDRLCHKTYLNGDHV THPDFMLYDALDVVLYMDPMCLDAF PKLVCFKKRIEAIPQIDKYLKSSKY IAWPLQGWQATFGGGDHPPKSDLE VLFQGPLGSAEKLSPNPPNLTKKMK KIVDAVIKYKDSSSGRQLSEVFIQL PSRKELPEYYELIRKPVDFKKIKER IRNHKYRSLNDLEKDVMLLCQNAQT FNLEGSLIYEDSIVLQSVFTSVRQK IEKEDDSE
• Purity: ≥96%
• Applications: Useful for the study of bromodomain binding assays, screening inhibitors, and selectivity profiling.
• Storage: >6 months at –80°C. Avoid freeze/thaw cycles.
• Concentration: 2.88 mg/ml

Gene Information

• Gene Name: SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 [ Homo sapiens (human) ]
• Official Symbol: SMARCA4
• Synonyms: SMARCA4; SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4; SNF2L4; transcription activator BRG1; ATP dependent helicase SMARCA4; BAF190; brahma protein like 1; BRG1; BRM/SWI2 related gene 1; FLJ39786; global transcription activator homologous sequence; homeotic gene regulator; hSNF2b; mitotic growth and transcription activator; nuclear protein GRB1; SNF2; SNF2 BETA; SNF2 like 4; SNF2LB; sucrose nonfermenting like 4; SWI2; BAF190A; SNF2-like 4; protein BRG-1; brahma protein-like 1; BRM/SWI2-related gene 1; protein brahma homolog 1; BRG1-associated factor 190A; sucrose nonfermenting-like 4; ATP-dependent helicase SMARCA4; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 4; RTPS2; SNF2-BETA
• Gene ID: 6597
• mRNA Refseq: NM_001128849
• Protein Refseq: NP_001122321
• MIM: 603254
• UniProt ID: P51532
• Chromosome Location: 19p13.2
• Pathway: Chromatin modifying enzymes; Chromatin organization; Integrated Breast Cancer Pathway; RMTs methylate histone arginines
• Function: ATP binding; DNA-dependent ATPase activity; contributes_to RNA polymerase II core promoter proximal region sequence-specific DNA binding

Reviews

02/18/2023

The SMARCA4 protein offers exceptional quality that meets the rigorous demands of experimental research.

11/01/2018

It exhibits exceptional performance in ELISA assays, making it an excellent choice for researchers studying angiopoietins, angiogenesis, or vascular biology.

10/30/2016

Its purity, consistency, and reliable performance make it a top choice for a wide range of applications.

Q&As

Can epigenetic therapies target SMARCA4 alterations?

Epigenetic therapies that modulate gene expression could indirectly affect SMARCA4-altered cancers, though specific targeting remains a challenge.

Are there diagnostic tests for SMARCA4 mutations?

Yes, there are genetic tests available to identify SMARCA4 mutations in tumors, aiding in prognosis and treatment decisions.

Are there ongoing clinical trials focusing on SMARCA4 alterations?

Yes, there are clinical trials exploring new treatment strategies for SMARCA4-altered cancers, aiming to improve patient outcomes.

Is SMARCA4 solely associated with cancer?

No, SMARCA4's functions extend beyond cancer and have implications in various biological processes, including development and differentiation.

How can SMARCA4 mutations influence patient prognosis?

Patients with SMARCA4 mutations in their tumors often face a poorer prognosis, which necessitates tailored treatment approaches.